News & Media
Newsroom
SK Life Science, Inc., Publishes Updated Real-World Experience on Cenobamate in Epilepsia Based on Recent 100,000 Patient Exposure Milestone
3.13.2024
Full Release
SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada
3.11.2024
Full Release
SK Life Science to Host Symposium and Present New Data at the American Epilepsy Society (AES) 2023 Annual Meeting
11.20.2023
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate fact sheet
For more information about epilepsy, please download this infographic
For more information about Lennox-Gastaut syndrome, please download this fact sheet
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
R&D Begins: 1993
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 8 compounds under clinical development